文献速递临床试验与 GCP流行病学与生物统计

无家可归者收容所居民流感即时分子检测与抗病毒治疗:阶梯楔形整群随机对照试验方案

Point-of-care molecular testing and antiviral treatment of influenza in residents of homeless shelters in Seattle, WA: study protocol for a stepped-wedge cluster-randomized controlled trial.
PubMed 文献 · Trials · 2020-11-23

本研究为阶梯楔形整群随机对照试验,在西雅图地区9个无家可归者收容所站点评估现场流感检测与抗病毒治疗能否减少流感传播。预计两个流感季纳入约3200名急性呼吸道疾病患者,主要终点为调整时间趋势后干预期与对照期的流感发病率。

要点

  • 现场即时流感检测并针对符合条件的患者给予抗病毒治疗,可能减少收容所内流感传播。
  • 研究采用阶梯楔形整群随机设计,所有站点先进入对照期,再随机时点转入干预期。
  • 主要终点为调整时间趋势后干预期与对照期的流感发病率比较。

核心结论

  • 该研究旨在评估收容所内现场检测与抗病毒治疗能否降低流感传播,目前为研究方案,尚无结果。

研究设计与样本

  • 阶梯楔形整群随机对照试验,在西雅图地区9个无家可归者收容所站点开展。
  • 所有站点每季开始时进入对照期进行常规监测,随后随机时点转入干预期。

关键数值与推荐

  • 急性呼吸道疾病定义为7天内出现2个及以上呼吸道症状,或新发/加重咳嗽。
  • 干预期对症状持续2天及以内的个体实施检测-治疗策略。
  • 流感检测阳性且症状出现48小时内,根据年龄和合并症给予巴洛沙韦或奥司他韦抗病毒治疗。
  • 主要终点为调整时间趋势后干预期与对照期的流感发病率。

临床怎么用

  • 在收容所等聚集性场所,可考虑对急性呼吸道疾病患者开展现场即时流感检测。
  • 对流感检测阳性且症状出现48小时内的患者,及时给予抗病毒治疗。

局限性

  • 本文为研究方案,尚无实际干预效果数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Influenza is an important public health problem, but data on the impact of influenza among homeless shelter residents are limited. The primary aim of this study is to evaluate whether on-site testing and antiviral treatment of influenza in residents of homeless shelters reduces influenza spread in these settings. METHODS AND ANALYSIS: This study is a stepped-wedge cluster-randomized trial of on-site testing and antiviral treatment for influenza in nine homeless shelter sites within the Seattle metropolitan area. Participants with acute respiratory illness (ARI), defined as two or more respiratory symptoms or new or worsening cough with onset in the prior 7 days, are eligible to enroll. Approximately 3200 individuals are estimated to participate from October to May across two influenza seasons. All sites will start enrollment in the control arm at the beginning of each season, with routine surveillance for ARI. Sites will be randomized at different timepoints to enter the intervention arm, with implementation of a test-and-treat strategy for individuals with two or fewer days of symptoms. Eligible individuals will be tested on-site with a point-of-care influenza test. If the influenza test is positive and symptom onset is within 48 h, participants will be administered antiviral treatment with baloxavir or oseltamivir depending upon age and comorbidities. Participants will complete a questionnaire on demographics and symptom duration and severity. The primary endpoint is the incidence of influenza in the intervention period compared to the control period, after adjusting for time trends. TRIAL REGISTRATION: ClinicalTrials.gov NCT04141917 . Registered 28 October 2019. Trial sponsor: University of Washington.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Newman KL, Rogers JH, McCulloch D, et al. Point-of-care molecular testing and antiviral treatment of influenza in residents of homeless shelters in Seattle, WA: study protocol for a stepped-wedge cluster-randomized controlled trial. Trials. 2020. PMID: 33228787. doi:10.1186/s13063-020-04871-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。